An Open Label, Single-Period, Phase 1 Study To Evaluate The Pharmacokinetics, Excretion Balance And Metabolism Of [14C]-PF04971729 In Healthy Adult Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Mar 2016
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 14 Apr 2015 Protocol has been amended to change in primary outcome, treatment and incl/excl criteria.
- 20 Jul 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2010 Planned initiation date changed from 1 May 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.